Printed from Voxsanity (voxsanity.com.au) — NCT06208150 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who have been diagnosed with multiple myeloma according to internationally recognised diagnostic standards, and whose disease can be measured through specific blood or urine tests at the time of screening.
People whose multiple myeloma has come back after previously responding to treatment, or whose disease has not responded adequately to previous treatment.
People whose multiple myeloma has gotten worse, or has not responded well enough, during or after their most recent treatment.
People who are reasonably well and able to carry out daily activities, as measured by a standard health performance scale (scores of 0, 1, or 2 on the ECOG scale).
People who agree not to be pregnant, breastfeeding, or planning to become pregnant while in the study or within 6 months after the last dose of study treatment.
Who may not be able to join:
People who have a known serious allergy, intolerance, or dangerous reaction to any of the study drugs or their ingredients.
People who have had a stroke, mini-stroke, or seizure within the 6 months before signing the consent form.
People who have had major surgery or a serious injury within 2 weeks before starting the study treatment, or who have not fully recovered from surgery, or who have planned major surgery during the treatment period or within 2 weeks after the last dose.
People who have received a high cumulative dose of steroid medication (equivalent to 140 mg or more of prednisone) within the 14 days before the first study dose.
People who have known or suspected multiple myeloma involvement in the brain or spinal fluid — unless specific brain scans and fluid tests come back negative (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT06208150
Sponsor: Janssen Research & Development, LLC
Phase: Phase 3
Status: Recruiting
Condition: Myeloma
Trial contact: 844-434-4210
More information: https://clinicaltrials.gov/study/NCT06208150
Eligibility summary (AI generated)
Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who have been diagnosed with multiple myeloma according to internationally recognised diagnostic standards, and whose disease can be measured through specific blood or urine tests at the time of screening.
People whose multiple myeloma has come back after previously responding to treatment, or whose disease has not responded adequately to previous treatment.
People whose multiple myeloma has gotten worse, or has not responded well enough, during or after their most recent treatment.
People who are reasonably well and able to carry out daily activities, as measured by a standard health performance scale (scores of 0, 1, or 2 on the ECOG scale).
People who agree not to be pregnant, breastfeeding, or planning to become pregnant while in the study or within 6 months after the last dose of study treatment.
Who may not be able to join:
People who have a known serious allergy, intolerance, or dangerous reaction to any of the study drugs or their ingredients.
People who have had a stroke, mini-stroke, or seizure within the 6 months before signing the consent form.
People who have had major surgery or a serious injury within 2 weeks before starting the study treatment, or who have not fully recovered from surgery, or who have planned major surgery during the treatment period or within 2 weeks after the last dose.
People who have received a high cumulative dose of steroid medication (equivalent to 140 mg or more of prednisone) within the 14 days before the first study dose.
People who have known or suspected multiple myeloma involvement in the brain or spinal fluid — unless specific brain scans and fluid tests come back negative (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
🇦🇷 Argentina
🇦🇺 Australia
🇦🇹 Austria
🇧🇪 Belgium
🇧🇷 Brazil
🇨🇦 Canada
🇨🇳 China
🇨🇿 Czechia
🇩🇰 Denmark
🇫🇷 France
🇩🇪 Germany
🇬🇷 Greece
🇭🇺 Hungary
🇮🇳 India
🇮🇱 Israel
🇮🇹 Italy
🇯🇵 Japan
🇲🇽 Mexico
🇳🇱 Netherlands
🇵🇱 Poland
🇸🇦 Saudi Arabia
🇰🇷 South Korea
🇪🇸 Spain
🇸🇪 Sweden
Turkey (Türkiye)
🇬🇧 United Kingdom
🇺🇸 United States
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Progression Free Survival (PFS)
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.